Literature DB >> 10373548

SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation.

S J Cohney1, D Sanden, N A Cacalano, A Yoshimura, A Mui, T S Migone, J A Johnston.   

Abstract

Members of the recently discovered SOCS/CIS/SSI family have been proposed as regulators of cytokine signaling, and while targets and mechanisms have been suggested for some family members, the precise role of these proteins remains to be defined. To date no SOCS proteins have been specifically implicated in interleukin-2 (IL-2) signaling in T cells. Here we report SOCS-3 expression in response to IL-2 in both T-cell lines and human peripheral blood lymphocytes. SOCS-3 protein was detectable as early as 30 min following IL-2 stimulation, while CIS was seen only at low levels after 2 h. Unlike CIS, SOCS-3 was rapidly tyrosine phosphorylated in response to IL-2. Tyrosine phosphorylation of SOCS-3 was observed upon coexpression with Jak1 and Jak2 but only weakly with Jak3. In these experiments, SOCS-3 associated with Jak1 and inhibited Jak1 phosphorylation, and this inhibition was markedly enhanced by the presence of IL-2 receptor beta chain (IL-2Rbeta). Moreover, following IL-2 stimulation of T cells, SOCS-3 was able to interact with the IL-2 receptor complex, and in particular tyrosine phosphorylated Jak1 and IL-2Rbeta. Additionally, in lymphocytes expressing SOCS-3 but not CIS, IL-2-induced tyrosine phosphorylation of STAT5b was markedly reduced, while there was only a weak effect on IL-3-mediated STAT5b tyrosine phosphorylation. Finally, proliferation induced by both IL-2- and IL-3 was significantly inhibited in the presence of SOCS-3. The findings suggest that when SOCS-3 is rapidly induced by IL-2 in T cells, it acts to inhibit IL-2 responses in a classical negative feedback loop.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10373548      PMCID: PMC84319          DOI: 10.1128/MCB.19.7.4980

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  32 in total

1.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  A family of cytokine-inducible inhibitors of signalling.

Authors:  R Starr; T A Willson; E M Viney; L J Murray; J R Rayner; B J Jenkins; T J Gonda; W S Alexander; D Metcalf; N A Nicola; D J Hilton
Journal:  Nature       Date:  1997-06-26       Impact factor: 49.962

3.  Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation.

Authors:  C L Yu; S J Burakoff
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

4.  Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.

Authors:  N A Cacalano; T S Migone; F Bazan; E P Hanson; M Chen; F Candotti; J J O'Shea; J A Johnston
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

5.  CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation.

Authors:  A Matsumoto; M Masuhara; K Mitsui; M Yokouchi; M Ohtsubo; H Misawa; A Miyajima; A Yoshimura
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

6.  Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.

Authors:  A L Mui; H Wakao; T Kinoshita; T Kitamura; A Miyajima
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

7.  Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2.

Authors:  J A Johnston; M Kawamura; R A Kirken; Y Q Chen; T B Blake; K Shibuya; J R Ortaldo; D W McVicar; J J O'Shea
Journal:  Nature       Date:  1994-07-14       Impact factor: 49.962

8.  Transcriptional activation by tetracyclines in mammalian cells.

Authors:  M Gossen; S Freundlieb; G Bender; G Müller; W Hillen; H Bujard
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

9.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.

Authors:  D Resnitzky; M Gossen; H Bujard; S I Reed
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

10.  A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors.

Authors:  A Yoshimura; T Ohkubo; T Kiguchi; N A Jenkins; D J Gilbert; N G Copeland; T Hara; A Miyajima
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

View more
  64 in total

1.  Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

Authors:  Daniela Ungureanu; Pipsa Saharinen; Ilkka Junttila; Douglas J Hilton; Olli Silvennoinen
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

2.  The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity.

Authors:  Ping Wang; Ning Li; Jie-Shou Li; Wei-Qin Li
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

3.  IL-4 confers resistance to IL-27-mediated suppression on CD4+ T cells by impairing signal transducer and activator of transcription 1 signaling.

Authors:  Zhihong Chen; Shanze Wang; Nkiruka Erekosima; Yapeng Li; Jessie Hong; Xiaopeng Qi; Patricia Merkel; Vijaya Nagabhushanam; Eugene Choo; Rohit Katial; Rafeul Alam; Anita Trikha; Hong Wei Chu; Yonghua Zhuang; Meiling Jin; Chunxue Bai; Hua Huang
Journal:  J Allergy Clin Immunol       Date:  2013-08-16       Impact factor: 10.793

4.  Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130.

Authors:  S E Nicholson; D De Souza; L J Fabri; J Corbin; T A Willson; J G Zhang; A Silva; M Asimakis; A Farley; A D Nash; D Metcalf; D J Hilton; N A Nicola; M Baca
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  C1QTNF1-AS1 regulates the occurrence and development of hepatocellular carcinoma by regulating miR-221-3p/SOCS3.

Authors:  Hang Li; Bo Zhang; Meng Ding; Shang Lu; Hui Zhou; Dajun Sun; Gang Wu; Xianfeng Gan
Journal:  Hepatol Int       Date:  2019-05-08       Impact factor: 6.047

6.  Suppressors of cytokine signaling 1 and 3 are upregulated in brain resident cells in response to virus-induced inflammation of the central nervous system via at least two distinctive pathways.

Authors:  Maria Abildgaard Steffensen; Christina Fenger; Jeanette Erbo Christensen; Carina Krogsgaard Jørgensen; Maria Rosaria Bassi; Jan Pravsgaard Christensen; Bente Finsen; Allan Randrup Thomsen
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

7.  Diet-induced obesity in mice reduces the maintenance of influenza-specific CD8+ memory T cells.

Authors:  Erik A Karlsson; Patricia A Sheridan; Melinda A Beck
Journal:  J Nutr       Date:  2010-06-30       Impact factor: 4.798

8.  Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation.

Authors:  Yoh-Ichi Seki; Katsuhiko Hayashi; Akira Matsumoto; Noriyasu Seki; Jun Tsukada; John Ransom; Tetsuji Naka; Tadamitsu Kishimoto; Akihiko Yoshimura; Masato Kubo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

9.  Tumor necrosis factor-a augments lipopolysaccharide-induced suppressor of cytokine signalling 3 (SOCS-3) protein expression by preventing the degradation.

Authors:  Jargalsaikhan Dagvadorj; Yoshikazu Naiki; Gantsetseg Tumurkhuu; Abu Shadat Mohammod Noman; Imtiaz Iftakhar-E-Khuda; Takayuki Komatsu; Naoki Koide; Tomoaki Yoshida
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

10.  The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients.

Authors:  Jeng-Ting Tsao; Chia-Chen Kuo; Shih-Chang Lin
Journal:  Clin Exp Med       Date:  2008-09-27       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.